NEW YORK – Abingdon Health and Abcam have inked a collaboration and comarketing agreement to identify opportunities for their products and services, including Abcam's reagent portfolio and Abingdon Health’s rapid test contract development and manufacturing services, the firms said on Tuesday.
Under the terms of the agreement, Cambridge, UK-based Abcam will be the preferred supplier of gold nanoparticles and custom conjugation reagents and services for lateral flow assays developed by York, UK-based Abingdon.
Financial and other terms of the agreement were not disclosed.
Abcam's custom conjugation reagents will include a combination of affinity binding reagents, such as antibodies, and signal reagents, such as colloidal gold that provides the color readout in a lateral flow assay.
"At a time when there is a shortage of such reagents in the market, this agreement secures a key supply chain for us," Abingdon’s CEO Chris Yates said in a statement. "This will also ensure our partners and customers will have certainty of delivery when they come to us to manufacture their tests."
Abingdon will work with Abcam "to identify and service their customers' lateral flow contract development and manufacturing requirements," he added.
Last July, Abingdon Health announced that a rapid point-of-care SARS-CoV-2 antibody test developed by it, a consortium of UK companies, and the University of Oxford had received the CE mark. In October, the UK government ordered 1 million antibody tests from Abingdon Health for use in surveillance studies of SARS-CoV-2.